{"created":"2025-02-21T03:22:17.120520+00:00","id":2006467,"links":{},"metadata":{"_buckets":{"deposit":"df7fe7e3-4835-4d27-9025-2682beae1c52"},"_deposit":{"created_by":41,"id":"2006467","owners":[41],"pid":{"revision_id":0,"type":"depid","value":"2006467"},"status":"published"},"_oai":{"id":"oai:hiroshima.repo.nii.ac.jp:02006467","sets":["1730444907710"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"The Pharmacokinetics of Low-Dose Thalidomide in Japanese Patients with Refractory Multiple Myeloma","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kamikawa, Rintaro","creatorNameLang":"en"}],"familyNames":[{"familyName":"Kamikawa","familyNameLang":"en"}],"givenNames":[{"givenName":"Rintaro","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Ikawa, Kazuro","creatorNameLang":"en"}],"familyNames":[{"familyName":"Ikawa","familyNameLang":"en"}],"givenNames":[{"givenName":"Kazuro","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Morikawa, Norifumi","creatorNameLang":"en"}],"familyNames":[{"familyName":"Morikawa","familyNameLang":"en"}],"givenNames":[{"givenName":"Norifumi","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Asaoku, Hideki","creatorNameLang":"en"}],"familyNames":[{"familyName":"Asaoku","familyNameLang":"en"}],"givenNames":[{"givenName":"Hideki","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Iwato, Koji","creatorNameLang":"en"}],"familyNames":[{"familyName":"Iwato","familyNameLang":"en"}],"givenNames":[{"givenName":"Koji","givenNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sasaki, Ayako","creatorNameLang":"en"}],"familyNames":[{"familyName":"Sasaki","familyNameLang":"en"}],"givenNames":[{"givenName":"Ayako","givenNameLang":"en"}]}]},"item_1617186476635":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"© 2006 Pharmaceutical Society of Japan"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"thalidomide","subitem_subject_scheme":"Other"},{"subitem_subject":"pharmacokinetics","subitem_subject_scheme":"Other"},{"subitem_subject":"multiple myeloma","subitem_subject_scheme":"Other"},{"subitem_subject":"490","subitem_subject_scheme":"NDC"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Thalidomide has been used for the treatment of refractory multiple myeloma, the dosage in Japan is lower than in other countries; however, there is little information on the pharmacokinetics and their relationship with the drug response. The aim of this study was to characterize the pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma, and to examine the relationship between pharmacokinetics and adverse events. On the first and second days, a 100 mg capsule was administered to 8 Japanese patients after breakfast and blood samples were obtained. The plasma concentrations were measured using HPLC and analyzed based on a one-compartment model. If intolerable adverse events were not observed for 14 d, the dose was increased to 200 mg. The average apparent volume of distribution (Vd/F), apparent total clearance (CL/F) and area under the plasma concentration–time curve from 0 to infinity (AUC0—∞), which were 45.3 l, 5.5 l/h and 21.7 μg·h/ml, respectively, with smaller Vd/F and CL/F and larger AUC0—∞ than in Caucasian populations. This pharmacokinetic difference may explain the dose difference between Japan and other countries. Adverse events were associated with AUC0—∞, which was best correlated with plasma concentration at 12 h after administration. The 12-h time point was suggested to be a capable indicator for “safety-oriented\" therapeutic drug monitoring of thalidomide.","subitem_description_language":"en"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"The Pharmaceutical Society of Japan"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"0918-6158","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":"1347-5215","subitem_source_identifier_type":"ISSN"},{"subitem_source_identifier":"AA10885497","subitem_source_identifier_type":"NCID"}]},"item_1617187024783":{"attribute_name":"Page Start","attribute_value_mlt":[{"subitem_start_page":"2331"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2006-11","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"11","bibliographicPageEnd":"2334","bibliographicPageStart":"2331","bibliographicVolumeNumber":"29","bibliographic_titles":[{"bibliographic_title":"Biological and Pharmaceutical Bulletin"},{"bibliographic_title":"Biological and Pharmaceutical Bulletin"}]}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1248/bpb.29.2331","subitem_relation_type_select":"DOI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1248/bpb.29.2331","subitem_relation_type_select":"DOI"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-03-18"}],"displaytype":"simple","filename":"BiolPhamBull_29_2331.pdf","filesize":[{"value":"109.0 KB"}],"mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://hiroshima.repo.nii.ac.jp/record/2006467/files/BiolPhamBull_29_2331.pdf"},"version_id":"e3fad158-f1dd-44a7-a153-21baceca2c53"}]},"item_1732771732025":{"attribute_name":"旧ID","attribute_value":"47053"},"item_title":"The Pharmacokinetics of Low-Dose Thalidomide in Japanese Patients with Refractory Multiple Myeloma","item_type_id":"40003","owner":"41","path":["1730444907710"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-03-18"},"publish_date":"2023-03-18","publish_status":"0","recid":"2006467","relation_version_is_last":true,"title":["The Pharmacokinetics of Low-Dose Thalidomide in Japanese Patients with Refractory Multiple Myeloma"],"weko_creator_id":"41","weko_shared_id":-1},"updated":"2025-02-21T07:39:06.664186+00:00"}